Which corporation is responsible for keytruda's patent?

Keytruda (pembrolizumab) is owned and patented by Merck & Co. Inc. (Merck, the U.S.‑based arm of the global company, known as MSD outside the United States). Merck holds the primary patents covering the drug’s active ingredient, formulation, manufacturing processes, and related use claims.